1. Home
  2. VYX vs AVTX Comparison

VYX vs AVTX Comparison

Compare VYX & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NCR Voyix Corporation

VYX

NCR Voyix Corporation

HOLD

Current Price

$8.77

Market Cap

1.1B

Sector

N/A

ML Signal

HOLD

Logo Avalo Therapeutics Inc.

AVTX

Avalo Therapeutics Inc.

HOLD

Current Price

$18.51

Market Cap

956.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VYX
AVTX
Founded
1881
2011
Country
United States
United States
Employees
13500
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
956.7M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
VYX
AVTX
Price
$8.77
$18.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
8
Target Price
$13.67
$40.57
AVG Volume (30 Days)
2.7M
1.9M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
72.07
EPS
N/A
N/A
Revenue
N/A
$27,813,137.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2312.27
52 Week Low
$6.02
$4.73
52 Week High
$14.67
$24.27

Technical Indicators

Market Signals
Indicator
VYX
AVTX
Relative Strength Index (RSI) 72.10 61.89
Support Level $6.29 $13.13
Resistance Level $10.24 $19.06
Average True Range (ATR) 0.48 1.32
MACD 0.13 0.37
Stochastic Oscillator 92.43 79.48

Price Performance

Historical Comparison
VYX
AVTX

About VYX NCR Voyix Corporation

NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in two reportable segments: Retail, and Restaurants. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The company derives maximum revenue from Retail segment. Geographically, the company operates in United States, Americas (excluding United States), Europe, Middle East and Africa, and Asia Pacific. It derives maximum revenue from United States.

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Share on Social Networks: